Testing Strategies to Improving Warfarin Adherence

University of Pennsylvania101 enrolled

Overview

We are performing a research study to learn more about the control of an individual's blood thinning (anticoagulation) on warfarin. Individuals from an anticoagulation clinic are being asked to participate in order to see if a lottery which provides the opportunity to win money in combination with the use of the Med-eMonitor might be useful in helping patients to achieve better control of their anticoagulation therapy. Half of the participants will be enrolled in the lottery arm and the other half will be a control group who will receive the Med-eMonitor only.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE

Enrollment

101

Conditions

Atrial Fibrillation Deep Venous Thrombosis Dilated Cardiomyopathies

Interventions

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 21 years old age or older * On warfarin managed at the AC clinic * Target INR 2.0-3.0 or 2.5-3.5 * At maintenance phase of therapy (defined as stable INR with stable warfarin dosing over at least 2 consecutive visits) Exclusion Criteria: * Do not have access to telephone line * Unwillingness to participate or to sign a consent form(refusal) * Inability to participate because of advances dementia, advanced Alzheimer's disease or other impairment affecting ability to provide informed consent and/or quality data or utilize the Med-eMonitor * Participation in a current study that does not permit participation in another study * End stage or terminal illness with anticipated life expectancy of 6 months or less * INR over the upper limit for the individual's range at the time of enrollment (e.g.,\>3.0 or \>3.5, depending on the target range) * Diagnosed with antiphospholipid antibody syndrome or abnormal INR prior to starting warfarin

Outcomes

Primary Outcomes

anticoagulation control

Time frame: six months

Secondary Outcomes

adherence